Literature DB >> 27596037

Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data.

Moses J Soka1, Mary J Choi2, April Baller3, Stephen White4, Emerson Rogers1, Lawrence J Purpura5, Nuha Mahmoud3, Christine Wasunna4, Moses Massaquoi1, Neetu Abad5, Jomah Kollie3, Straker Dweh4, Philip K Bemah1, Athalia Christie5, Victor Ladele3, Oneykachi C Subah4, Satish Pillai5, Margaret Mugisha3, Jonathan Kpaka4, Stephen Kowalewski5, Emilio German5, Mark Stenger5, Stuart Nichol5, Ute Ströher5, Kristin E Vanderende5, Shauna Mettee Zarecki5, Hugh Henry W Green5, Jeffrey A Bailey6, Pierre Rollin5, Barbara Marston5, Tolbert G Nyenswah1, Alex Gasasira3, Barbara Knust5, Desmond Williams5.   

Abstract

BACKGROUND: Ebola virus has been detected in semen of Ebola virus disease survivors after recovery. Liberia's Men's Health Screening Program (MHSP) offers Ebola virus disease survivors semen testing for Ebola virus. We present preliminary results and behavioural outcomes from the first national semen testing programme for Ebola virus.
METHODS: The MHSP operates out of three locations in Liberia: Redemption Hospital in Montserrado County, Phebe Hospital in Bong County, and Tellewoyan Hospital in Lofa County. Men aged 15 years and older who had an Ebola treatment unit discharge certificate are eligible for inclusion. Participants' semen samples were tested for Ebola virus RNA by real-time RT-PCR and participants received counselling on safe sexual practices. Participants graduated after receiving two consecutive negative semen tests. Counsellors collected information on sociodemographics and sexual behaviours using questionnaires administered at enrolment, follow up, and graduation visits. Because the programme is ongoing, data analysis was restricted to data obtained from July 7, 2015, to May 6, 2016.
FINDINGS: As of May 6, 2016, 466 Ebola virus disease survivors had enrolled in the programme; real-time RT-PCR results were available from 429 participants. 38 participants (9%) produced at least one semen specimen that tested positive for Ebola virus RNA. Of these, 24 (63%) provided semen specimens that tested positive 12 months or longer after Ebola virus disease recovery. The longest interval between discharge from an Ebola treatment unit and collection of a positive semen sample was 565 days. Among participants who enrolled and provided specimens more than 90 days since their Ebola treatment unit discharge, men older than 40 years were more likely to have a semen sample test positive than were men aged 40 years or younger (p=0·0004). 84 (74%) of 113 participants who reported not using a condom at enrolment reported using condoms at their first follow-up visit (p<0·0001). 176 (46%) of 385 participants who reported being sexually active at enrolment reported abstinence at their follow-up visit (p<0·0001).
INTERPRETATION: Duration of detection of Ebola virus RNA by real-time RT-PCR varies by individual and might be associated with age. By combining behavioural counselling and laboratory testing, the Men's Health Screening Program helps male Ebola virus disease survivors understand their individual risk and take appropriate measures to protect their sexual partners. FUNDING: World Health Organization and the US Centers for Disease Control and Prevention. ©2016 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27596037     DOI: 10.1016/S2214-109X(16)30175-9

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN: 2214-109X            Impact factor:   26.763


  43 in total

1.  Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys.

Authors:  Xiankun Zeng; Candace D Blancett; Keith A Koistinen; Christopher W Schellhase; Jeremy J Bearss; Sheli R Radoshitzky; Shelley P Honnold; Taylor B Chance; Travis K Warren; Jeffrey W Froude; Kathleen A Cashman; John M Dye; Sina Bavari; Gustavo Palacios; Jens H Kuhn; Mei G Sun
Journal:  Nat Microbiol       Date:  2017-07-17       Impact factor: 17.745

2.  Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Authors:  Angela Huttner; Selidji Todagbe Agnandji; Christophe Combescure; José F Fernandes; Emmanuel Bache Bache; Lumeka Kabwende; Francis Maina Ndungu; Jessica Brosnahan; Thomas P Monath; Barbara Lemaître; Stéphane Grillet; Miriam Botto; Olivier Engler; Jasmine Portmann; Denise Siegrist; Philip Bejon; Peter Silvera; Peter Kremsner; Claire-Anne Siegrist
Journal:  Lancet Infect Dis       Date:  2018-04-05       Impact factor: 25.071

Review 3.  Insights from clinical research completed during the west Africa Ebola virus disease epidemic.

Authors:  Amanda Rojek; Peter Horby; Jake Dunning
Journal:  Lancet Infect Dis       Date:  2017-04-28       Impact factor: 25.071

4.  Ebola virus lingers longer than scientists thought.

Authors:  Erika Check Hayden
Journal:  Nature       Date:  2016-09-15       Impact factor: 49.962

5.  A Longitudinal Study of Ebola Sequelae in Liberia.

Authors:  Michael C Sneller; Cavan Reilly; Moses Badio; Rachel J Bishop; Allen O Eghrari; Soka J Moses; Kumblytee L Johnson; Dehkontee Gayedyu-Dennis; Lisa E Hensley; Elizabeth S Higgs; Avindra Nath; Kaylie Tuznik; Justin Varughese; Kenneth S Jensen; Bonnie Dighero-Kemp; James D Neaton; H Clifford Lane; Mosoka P Fallah
Journal:  N Engl J Med       Date:  2019-03-07       Impact factor: 91.245

6.  Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles.

Authors:  Haoyang Li; Fei Yu; Shuai Xia; Yufeng Yu; Qian Wang; Ming Lv; Yan Wang; Shibo Jiang; Lu Lu
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 7.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

8.  Screening of genital fluid for Ebola virus.

Authors:  William A Fischer; Amy J Loftis; David A Wohl
Journal:  Lancet Glob Health       Date:  2017-01       Impact factor: 26.763

9.  Rigorous surveillance is necessary for high confidence in end-of-outbreak declarations for Ebola and other infectious diseases.

Authors:  Robin N Thompson; Oliver W Morgan; Katri Jalava
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-07-08       Impact factor: 6.237

Review 10.  Ebola virus disease: an update on post-exposure prophylaxis.

Authors:  William A Fischer; Pauline Vetter; Daniel G Bausch; Timothy Burgess; Richard T Davey; Robert Fowler; Frederick G Hayden; Peter B Jahrling; Andre C Kalil; Douglas L Mayers; Aneesh K Mehta; Timothy M Uyeki; Michael Jacobs
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.